Novel Synthetic Drugs in Migraine

ISBN-13: 9783030953362 / Angielski

Paolo Martelletti; Lars Edvinsson

Spis treści

Preface

Foreword

1. Novel Pharmacological Targets of Migraine: An Overview​

2. Molecular and cellular mechanisms of CGRP antagonists

3. Atogepant

4. Ubrogepant 

5. Rimegepant

6. Zavegepant

7. Molecular mechanisms of 5-HT1F receptor agonists

8. Lasmitidan

9. Update on old and current targets for anti-migraine therapies

O autorze

Paolo Martelletti is Professor of Internal Medicine at the University 'La Sapienza' of Rome, and Director of the Regional Reference Headache Center at the Sant'Andrea University Hospital in Rome, Italy. He is now developing new research avenues for the study of factors for chronicity, comorbidities, and aspects of health economics in primary headaches; elaboration of rehabilitation protocols in patients with secondary headache as a consequence of medication overuse; study of innovative therapies for the acute treatment and prophylaxis of primary headaches. He is Editor of the Springer Headache book series and Editor-in-Chief of the Journal of Headache and Pain and Editor-in-Chief of Springer Nature Comprehensive Clinical Medicine.

​Lars Edvinsson is Professor of Internal Medicine at the  Faculty of Medicine, Lund University Hospital, Sweden. He is a leading expert in the field of  cerebral circulation and  migraine and is  world recognized for his work on vascular innervation and receptor regulation. His extensive research has been a major contributor to what is known about the roles of the cerebral vasculature in health and diseases such as stroke and primary headaches. Recently, his ground-breaking work on the sensory system has resulted in new medicine being introduced small molecular CGRP-blockers for acute attacks and antibodies towards CGRP or CGRP-receptors as prophylaxis chronic migraine.                    

Blurb

Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development.